Kruse K
Department of Pediatrics, Medical University of Luebeck, Germany.
J Pediatr. 1995 May;126(5 Pt 1):736-41. doi: 10.1016/s0022-3476(95)70401-9.
To improve understanding of the biochemical events in vitamin D-deficiency rickets (VDR).
We investigated 51 untreated patients, 2 to 36 months of age, during three stages of VDR. Nineteen of these patients were also studied during therapy with 5000 to 10,000 U vitamin D3 (cholecalciferol) and 0.5 to 1 gm calcium. Together with calcium and inorganic phosphate in serum and urine, we measured (1) parathyroid hormone (PTH) secretion (intact serum PTH) and action on the kidney (urinary adenosine 3',5'-cyclic monophosphate (cAMP)/creatinine ratio; (2) serum alkaline phosphatase level; (3) urinary hydroxyproline/creatinine ratio; and (4) serum 1,25-dihydroxyvitamin D (1,25(OH)2D) level.
The untreated patients had secondary hyperparathyroidism (high serum PTH and urinary cAMP/creatinine ratio), low calcium and phosphate concentrations in serum, and increased bone turnover (elevated serum alkaline phosphatase and OHP/creatinine ratio), whereas serum 1,25(OH)2D was low, normal, or even slightly elevated. Serum calcium level was positively correlated to serum 1,25(OH)2D and to OHP/creatinine ratio, indicating that normocalcemia in untreated rickets (stage 2) is at least partially maintained by 1,25(OH)2D-induced calcium mobilization from bone. There was no correlation between serum calcium and serum PTH, or between serum PTH and urinary cAMP/creatinine ratio or serum phosphate, indicating disturbed regulation and action of PTH. During vitamin D treatment, serum 1,25(OH)2D values increased to supranormal concentrations in association with the restoration of the physiologic relationship of PTH to serum calcium and phosphate concentrations and urinary cAMP/creatinine ratio.
Circulating 1,25(OH)2D has an important role in the pathophysiology of VDR before and during treatment, mainly by influencing the bone and kidney response to endogenous PTH.
提高对维生素D缺乏性佝偻病(VDR)生化事件的认识。
我们研究了51例年龄在2至36个月、处于VDR三个阶段的未经治疗的患者。其中19例患者在接受5000至10000 U维生素D3(胆钙化醇)和0.5至1 g钙治疗期间也进行了研究。除了血清和尿液中的钙和无机磷酸盐外,我们还测量了:(1)甲状旁腺激素(PTH)分泌(血清完整PTH)及其对肾脏的作用(尿腺苷3',5'-环磷酸(cAMP)/肌酐比值);(2)血清碱性磷酸酶水平;(3)尿羟脯氨酸/肌酐比值;以及(4)血清1,25-二羟维生素D(1,25(OH)2D)水平。
未经治疗的患者存在继发性甲状旁腺功能亢进(血清PTH和尿cAMP/肌酐比值升高),血清钙和磷浓度降低,骨转换增加(血清碱性磷酸酶和OHP/肌酐比值升高),而血清1,25(OH)2D水平较低、正常或甚至略有升高。血清钙水平与血清1,25(OH)2D以及OHP/肌酐比值呈正相关,表明未经治疗的佝偻病(第2阶段)中的正常血钙至少部分是由1,25(OH)2D诱导的骨钙动员维持的。血清钙与血清PTH之间以及血清PTH与尿cAMP/肌酐比值或血清磷之间均无相关性,表明PTH的调节和作用受到干扰。在维生素D治疗期间,血清1,25(OH)2D值升高至超正常浓度,同时PTH与血清钙和磷浓度以及尿cAMP/肌酐比值的生理关系得以恢复。
循环中的1,25(OH)2D在VDR治疗前和治疗期间的病理生理学中起重要作用,主要是通过影响骨骼和肾脏对内源性PTH的反应。